Compass Therapeutics, Inc.
157.4M
$247.53M
-12.74
$-0.42
No price alerts set. Add an alert to get notified!
-12.74
4.30
$-0.42
-33.79%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics plc
|
$4.77 | -1.45% | -1.51 | $330.38M | 0.03 |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$15.92 | -1.00% | -82.26 | $1.34B | 0.02 |
|
FDMT
4D Molecular Therapeutics, Inc.
|
$9.45 | 0.53% | -3.91 | $482.44M | 0.04 |
|
FULC
Fulcrum Therapeutics, Inc.
|
$7.72 | -1.53% | -7.73 | $417.74M | 0.02 |
|
GOSS
Gossamer Bio, Inc.
|
$0.35 | -3.92% | -0.46 | $81.79M | -1.65 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$19.16 | -2.39% | -5.79 | $981.42M | -104.83 |
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$1.69 | 0.60% | -12.20 | $716.02M | 0.58 |
|
MNPR
Monopar Therapeutics Inc.
|
$54.02 | 1.54% | -26.36 | $361.51M | 0.00 |
|
OCGN
Ocugen, Inc.
|
$1.70 | 2.41% | -7.83 | $557.42M | -2.72 |
|
OMER
Omeros Corporation
|
$14.74 | 8.94% | -279.44 | $1.06B | -1.97 |
* Peer stocks are selected based on market capitalization and sector
$6.88
$1.61
$0.00
0.00%
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
